Oklahoma State University

The University of Oklahoma

Board of Regents for the Oklahoma Agricultural & Mechanical Colleges

Other

The Board of Regents of the University of Ok

Jacobson Resonance Enterprises, Inc.

Benjamin J Scherlag

Kenneth D Berlin

Mark D Thompson

Gary S Smith

Subbiah Sangiah

Jerry I Jacobson

William S Yamanashi

Sunny Po

Ralph Lazzara

Eugene S Patterson

Surendra R Otiv

Stan A Zisman

Gregory Lynn Garrison

Satish V Mulekar

Chun-Lin Chen

Cyril Roy Clarke

George Edward Burrows

Cyril R Clarke

David E Albert

Wilton W Webster, Jr

Kenneth J Dormer

Elizabeth M Holt

Michael Scherlag

Stavros Stavrakis

Patrick Schauerte

Paul Garabelli

Carey N Pope

Bruce R Bailey, Iii

Methods and systems for alleviating disorders and complications associated with autonomic nervous system dysfunction. The approach generally includes measuring heart rate signals from a subject to measure heart rate variability and determine a heart rate variability threshold, determining that the subject is experiencing autonomic nervous system dysfunction, and alerting the subject to stimulate the auricular branch of the vagus nerve with an ear device.

System and method for treating autonomic nervous system dysfunctions

The present disclosure describes a method for targeted delivery of permanently-acting or temporarily-acting neurotoxins, neurosuppressants, or other compounds having a neurologic effect to specific locations of the heart, including for example, but not limited to, nodes of the cardiac autonomic nervous system such as the atrial ganglionated plexi (GP). Chemical ablation of the atrial GP as described herein via magnetically-targeted magnetically-susceptible nanoparticles can effectively suppress GP activity and atrial fibrillation related, thereto without permanent damage to either myocardium or intrinsic CANS.

Magnetically-targeted treatment for cardiac disorders

Disclosed are methods of treatment or prophylaxis of a disease state or a condition ameliorated or prevented by electromagnetic field application. A person having or susceptible to such disease state or condition is subjected to electromagnetic fields having a frequency between zero and about 200 Hertz. The diseased state or condition may include diseased heart valves, an enlarged heart, circulatory blockage, coronary insufficiencies, and ischemia. The treatment may be administered non-invasively or invasively. An implantable device for invasively administering the treatment may include at least one component emitting electromagnetic fields having a frequency between zero and about 200 Hertz. The component may include at least one inductor.

Cardioelectromagnetic treatment

A method of treatment or prophylaxis of a disease state or a condition ameliorated or prevented by electromagnetic field application. A person having or susceptible to such disease state or condition is subjected to electromagnetic fields having a frequency between zero and about 200 Hertz. The diseased state or condition may include diseased heart valves, an enlarged heart, circulatory blockage, coronary insufficiencies, and ischemia. The treatment may be administered non-invasively or invasively. An implantable device for invasively administering the treatment may include at least one component emitting electromagnetic fields having a frequency between zero and about 200 Hertz. The component may include at least one inductor.

The present invention provides a method of controlling cardiac fibrillation, tachycardia, or cardiac arrhythmia by the use of an electrophysiology catheter having a tip section that contains at least one stimulating electrode, the electrode being stably placed at a selected intravascular location. The electrode is connected to a stimulating means, and stimulation is applied across the wall of the vessel, transvascularly, to a sympathetic or parasympathetic nerve that innervates the heart at a strength sufficient to depolarize the nerve and effect the control of the heart.

Method and apparatus for transvascular treatment of tachycardia and fibrillation

3,7-Diazabicyclo�3.3!nonanes and selected derivatives thereof of the general formula: ##STR1## wherein Q=S; Z=CH.sub.2 ; and Y equals an N-acyl or N-alkyl group are disclosed as multiclass antiarrhythmic agents.

N-alkyl and N-acyl derivatives of 3,7-Diazabicyclo-�3.3.1!nonanes and

3,7-Diazabicyclo[3.3.1]nonanes and selected derivatives thereof of the general formula: ##STR1## are disclosed as multiclass antiarrhythmic agents.

N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and

A method for alleviating and diagnosing syndromes of heart block wherein a stimulus is continuously or intermittently delivered via a single electrode catheter at a site in a heart in close proximity to the A-V junction in the heart. The subthreshold stimuli were sufficient to cause impulses in the atrium to pass through the damaged His bundle to the ventricle and the stimuli were set at a level below a level required to excite the heart tissue. The delivery of the stimuli alleviates the symptoms of heart block. In one application, the delivery of the stimuli is used for diagnosing heart block when delivery of the stimuli induces the symptoms of heart block in the patient with partial or covert conduction disease.

Method for alleviating and diagnosing symptoms of heart block

3-7-Diheterabicyclo[3.3.1]nonanes and derivatives thereof are disclosed. Their method of preparation and use as antiarrhythmic agents is given.

3-7-diheterabicyclo (3.3.1)nonanes and derivatives as antiarrhythmic

Salts of 3-azabicyclo[3.3.1]nonanes are used in controlling antiarrhythmic processes and precursors thereof are disclosed.

Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and

Salts of 3-azabicyclo [3.3.1]nonanes as antiarrhythmic agents, and

3-7-Diheterabicylo[3.3.1]nonanes and derivatives thereof are disclosed. Their method of preparation and use as antiarrhythmic agents is given.

Bis-1,3-diazine heterocyclic derivatives as antiarrhythmic agents

Polyheterobicyclotridecane compounds

3-7,Diheterabicylo[3.3.1]nonanes and derivatives thereof are disclosed. Their method of preparation and use as antiarrhythmic agents is given.

Growing community of inventors

Oklahoma City, OK, United States of America

Benjamin J Scherlag